MHT and Mortality: Reassuring Data From a New Study
A new nationwide Danish cohort study of over 800,000 women examined long‑term menopausal hormone therapy (MHT) and mortality. Researchers tracked participants for an average of 14.3 years, including more than 100,000 MHT users, some with ten or more years of exposure. The analysis found no overall increase or decrease in all‑cause mortality, cardiovascular or cancer deaths, even with prolonged use. However, women who had bilateral oophorectomy experienced a 27‑34% mortality reduction, suggesting a distinct benefit in that subgroup.
ATP Depletion the Key Driver of Ferroptosis in Alzheimer’s Brains
Recent research highlights three distinct breakthroughs: administering cancer immunotherapy earlier in the day can slash patient mortality, a novel fluorescent sensor enables instant detection of E. coli in catheter bags to curb urinary‑tract infections, and digital‑twin models are being used...
3D Printing Is Now Possible Inside Living Cells
Researchers have unveiled a suite of breakthroughs that could reshape bio‑manufacturing and quantum technology. An AI‑driven digital light processing resin now permits 3D printing directly inside living cells, opening pathways for cellular‑level tissue engineering. Parallel studies revealed anomalous reverse heat...
What Are Biologics and Small Molecules for Ulcerative Colitis?
Advanced therapies—biologics and small molecules—offer targeted treatment for moderate to severe ulcerative colitis. Biologics are injectable antibodies that block specific immune proteins, while small molecules are oral agents that inhibit intracellular inflammatory pathways. Clinical experience shows remission often begins within...
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria (ASX:EMD) has launched the Empax Global Partnership Platform, giving international drug sponsors and CROs direct access to its clinical delivery infrastructure for complex psychedelic‑assisted therapies. The service creates a dual‑revenue model that blends existing reimbursed treatment programs with high‑margin,...
Salt Harms Arteries via Immune‑driven Senescence, Not Direct Toxicity
Salt has been blamed as the culprit for damaging your arteries. A new mouse study puts salt-sensitive hypertension in context. Salt doesn't do it directly, it triggers your immune system to do it. 4 weeks on a high-salt diet (8% NaCl) cut...
Trump Cuts Crucial Health Research Funding, Fueling Crisis
This piece in the WaPo summarizes what I've been say. The feds under Trump are choking off research dollars -- particularly for women's health, cancer and mental health. Young researchers are particularly hard hit, steering scientists into other work. It's...
FDA Seeks More Cardiovascular Data on Eli Lilly’s Orforglipron After Safety Concerns
The U.S. FDA has asked Eli Lilly to provide further cardiovascular safety data on its newly approved oral GLP‑1 weight‑loss drug Orforglipron, after the agency’s approval letter flagged “unexpected serious risks.” Lilly says patient safety remains its top priority as it...
Boosting Mitochondrial NAD+/NADH Extends Life, Eases Alzheimer’s
Extension of Lifespan and Amelioration of Alzheimer's Disease Phenotypes by Genetic Manipulation of Mitochondrial NAD+/NADH Ratio https://t.co/m8K1Tm9sIR https://t.co/SU85G9FsgW
Alembic Pharma Secures US FDA Nod for Generic Methotrexate Injection, Boosting US Generics Portfolio
Alembic Pharmaceuticals announced US FDA approval for its generic methotrexate injection USP on April 16, 2026. The clearance covers 50 mg/2 mL multi‑dose and 1 g/40 mL single‑dose vials, bringing the Indian drugmaker’s total US ANDA approvals to 236. The move strengthens Alembic’s foothold...
Gene‑Therapy Pioneers Win $3 Million Breakthrough Prize for Vision and Sickle‑Cell Treatments
The Breakthrough Prize Foundation awarded a $3 million Life Sciences prize to three University of Pennsylvania scientists and two collaborators for pioneering gene‑therapy treatments that restore sight in Leber congenital amaurosis and target sickle‑cell disease. The honor spotlights Luxturna’s market entry...
Zombie Immune Cells Linked to Fatty Liver, Inflammation, Aging
UCLA scientists identify zombie immune cells as a driver of fatty liver disease, inflammation and aging https://t.co/28Ql5er4kb https://t.co/IoAD5I6AJr
FDA Approves Breakthrough Therapy for Critically Ill Children
FDA says ‘yes’ to transformative therapy for sick children — and more media coverage of UCLA https://t.co/N6AJsRwCyX
Pinnacle Food Group Develops Breakthrough Process for Recombinant Breast Milk Protein at Hong Kong Lab
Canadian biotech Pinnacle Food Group announced a methanol‑free precision‑fermentation process that produces recombinant human lactoferrin using a patented Pichia yeast strain at its Hong Kong lab. The new method eliminates toxic methanol, reducing capital and operating expenses while delivering a...
Eli Lilly to Spend $6.3 B on Centessa Buy, with up to $1.5 B in Milestone Payouts
Eli Lilly agreed to acquire UK‑based Centessa Pharmaceuticals for an upfront $6.3 billion, plus a contingent value right that could add $1.5 billion if the lead sleep‑wake disorder drug meets regulatory milestones. The deal, priced at a 40% premium, follows Lilly’s cash‑rich...
NTU Unveils AI‑Powered Biochip That Detects Disease Biomarkers in 20 Minutes
Scientists at Singapore’s Nanyang Technological University have built an AI‑driven nanophotonic biochip that can identify disease‑related microRNA biomarkers in roughly 20 minutes. The prototype pairs a camera and mobile app for real‑time analysis, aiming to cut diagnostic turnaround times dramatically.
Axtria Acquires Conexus Solutions to Add AI‑Powered CRM for Life‑Sciences Companies
Axtria announced the acquisition of Conexus Solutions, a Veeva and Salesforce‑focused CRM transformation partner, to embed end‑to‑end CRM capabilities into its AI‑first data analytics suite for life‑sciences firms. While the financial terms were not disclosed, the deal is positioned as...
Combined NMN and CD38 Inhibitor Rejuvenates Aging Muscles
Double-Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration https://t.co/bnkkn0xblj Scheme 1: A novel synergistic drug combination (N + A) consisting of an NAD+ precursor (NMN) and an NAD+ consumption (CD38) inhibitor (API) promotes musculoskeletal regeneration in aging.
FDA Grants Breakthrough Therapy Designation to Plixorafenib for Rare CNS Tumors
The U.S. FDA has granted Breakthrough Therapy Designation to plixorafenib, an investigational BRAF inhibitor for adults with rare, high‑grade gliomas harboring the BRAF V600E mutation. Early‑stage data showed a 67% overall response rate, positioning the drug as a potential game‑changer...
Single-Cell Transcriptomics of Human Brain Disorders
A surge of single‑cell and single‑nucleus transcriptomic studies is redefining the molecular architecture of Alzheimer’s disease and related brain disorders. Researchers have cataloged dozens of cell‑type specific signatures, from microglial states driven by TREM2 variants to endothelial and astrocyte dysregulation....
Nano-X Imaging Ltd (NNOX) Q4 2025 Earnings Call Transcript
Nyxoah (NNOX) reported its first full quarter of U.S. commercialization after the August 2025 FDA approval of its Genio hypoglossal nerve stimulation system. Q4 2025 generated €3.5 million in U.S. net revenue and €5.6 million globally, with a 64% gross margin, while...
AI-Optimized Molecules Drive Clinical Interest and Expansion
#AACR2026 is in full swing and our posters are very popular. And some pharma companies realized that we have clinical data now and the molecules were AI-optimized to avoid the common liabilities. Finally, some genuine interest and we will have...
HIV Treatment Reduces Accelerated Biological Aging by Nearly Four Years, Landmark Study Shows
A landmark study presented at ESCMID Global 2026 shows that antiretroviral therapy (ART) reduces the accelerated biological aging seen in people with HIV (PWH) by an average of 3.7 years after roughly 1.5 years of treatment. Researchers used a plasma...
Antibiotic Resistance Genes Found in Newborns Within Hours of Birth, Study Shows
A new ESCMID Global 2026 study examined meconium from 105 NICU infants and found antibiotic resistance genes (ARGs) within hours of birth. The most prevalent genes were oqxA (98%) and qnrS (96%), with beta‑lactamase genes such as blaCTX‑M present in...
A Light-Controlled 'Muscle' Could Give Synthetic Cells a New Way to Move
Engineers at Georgia Tech have created a light‑controlled protein network that mimics a muscle, using calcium‑triggered contraction instead of ATP‑driven motors. The system relies on the ciliate protein Tcb2 and a light‑sensitive calcium cage to release calcium on demand, achieving...
Here’s Simulations Plus Inc (SLP)’s Vision for AI in Drug Development
Simulations Plus Inc (NASDAQ:SLP) announced on March 26 that three major pharmaceutical firms have joined its AI‑enabled modeling collaboration programs, embedding the company’s AI agents directly into their drug‑development workflows. The firm emphasized a fully integrated AI deployment rather than...
Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership
Recursion Pharmaceuticals announced an expanded partnership with Citeline on March 31, adding the data‑provider’s real‑world evidence capabilities to its AI‑driven drug discovery platform. The integration is designed to improve clinical‑trial design and accelerate decision‑making for its pipeline of cancer and...
Leaked Images Show Monkeys Forced Into Weight‑Loss Drug Tests in UK Labs
A former laboratory technician leaked graphic footage of long‑tailed macaques being restrained and fed experimental anti‑obesity drugs via oral gavage in two UK facilities. The images, obtained by The Mail on Sunday, have ignited calls for faster phasing out of...
FDA Clears UNC AI Ultrasound Tool, Expanding Prenatal Care Access
The U.S. Food and Drug Administration has cleared an artificial‑intelligence system created at the University of North Carolina that estimates fetal gestational age from standard ultrasound video. Licensed to Butterfly Network, the tool can now be used clinically across the...
Cubical Bipyramid Nanoparticles Enable Systemic Magnetic Hyperthermia for Ovarian Cancer
Researchers at Oregon State University have created a cubical bipyramid magnetic nanoparticle that can be delivered intravenously and heated to 42‑46 °C under an alternating magnetic field, overcoming the need for direct tumor injection. The breakthrough, published in Advanced Functional Materials,...
FDA Expands Vertex's Alyftrek, Trikafta Labels to Reach 95% of U.S. Cystic Fibrosis Patients
The U.S. Food and Drug Administration approved label extensions for Vertex Pharmaceuticals' CF drugs Alyftrek and Trikafta, now covering roughly 95% of cystic fibrosis patients in the United States. The expansion adds eligibility for about 800 more patients, based on...
Novel Diabetic Wound Treatment Turns Cells Into Manufacturers
Researchers at Texas A&M have created a novel wound dressing for diabetic foot ulcers that leverages an interwoven extracellular matrix produced by human cells, then strips the cells away, leaving a purely biological scaffold. The approach sidesteps the immune‑rejection and...
Rogan Tipped the Scales on Psychedelic Research in the US
Joe Rogan appeared at the White House as President Trump signed an executive order to fast‑track psychedelic research and clinical trials. The directive directs federal agencies to accelerate approval pathways for psychedelic therapeutics aimed at PTSD, veteran mental health, and...
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Revolution Medicines reported Phase III RASolute 302 results showing its oral RAS inhibitor daraxonrasib extended median overall survival to 13.2 months in previously treated metastatic pancreatic ductal adenocarcinoma, versus 6.7 months for standard chemotherapy (HR 0.40, p < 0.0001). The data sparked a...
What to Know Before Buying GLP-1 Drugs Online
The FDA warns that many online ads for GLP‑1 weight‑loss drugs promote compounded versions that lack the rigorous testing of brand‑name products like Ozempic, Wegovy, and Mounjaro. These compounded formulations can vary in concentration, contain unapproved ingredients, and have been...
Can a Common Parasite Medication Calm the Brain’s Stress Circuitry During Alcohol Withdrawal?
Researchers at UC San Diego discovered that rodents with high P2rx4 gene expression exhibit markedly increased alcohol consumption during withdrawal. Administering the antiparasitic drug ivermectin produced a dose‑dependent reduction in lever‑pressing for alcohol, especially in animals that responded behaviorally. Electrophysiological...
Lung‑resident Memory B Cells Drive Lasting Flu Protection
Long-term flu protection may depend on lung-resident memory B cells, whose persistence is shaped by the strength of B cell receptor signaling, offering new directions for vaccines targeting immune defenses within lung tissue. immunology
Nrf2 Activation Offers Therapeutic Promise, Yet Requires Caution
Nrf2 Activation in Inflammatory Diseases: A Review of Natural and Synthetic Modulators 🔑 Mechanistic insights and preclinical and clinical evidence on the role of Nrf2 in inflammatory diseases and evaluates the therapeutic potential of its key activators. “ The nuclear factor...
Joe Rogan Reveals Trump IMMEDIATELY Offered Him FDA Approval for Unbelievable New Treatment...
President Donald Trump issued an executive order accelerating federal research on ibogaine, a Schedule I psychedelic, to create FDA pathways for veteran mental‑health treatment. The order follows claims that ibogaine can address depression, PTSD and substance abuse, with the FDA expected...
AI-Designed Enzymes Poised to Replace Petrochemicals in Everyday Products
The detergent you use. The fabric on your Gore-Tex jacket. The fragrance in your shampoo. For a century, making these products meant petrochemicals and harsh industrial chemistry. AI protein design is changing the underlying process. @ArzedaCo builds custom enzymes for real...
Dasatinib and Quercetin as Senolytic May Cause Brain Damage
A March 2026 PNAS study shows that the senolytic combo dasatinib and quercetin (D+Q) triggers demyelination in the corpus callosum of aged mice. The researchers used intermittent oral doses of 5 mg/kg dasatinib and 50 mg/kg quercetin, identical to regimens linked to...
USC Compound Halts Alzheimer-Linked Brain Inflammation
As a medical school professor at USC, this one is personal. My colleagues at Keck School of Medicine developed a compound that stops brain inflammation linked to Alzheimer's -- while preserving normal brain function. The target: cPLA2, an enzyme that drives inflammation...
Stop Pipetting Yourself—Let Us Handle Experiments
Humans weren’t meant to pipette. Time to move on. Happy to run your experiments for you at https://t.co/b8gQiWKIwy https://t.co/skmzANp2Sl
FGF21 Hormone Shows Promise to Reverse Obesity in Preclinical Study
Scientists have demonstrated that fibroblast growth factor 21 (FGF21) activates hindbrain circuits to increase energy expenditure, reversing obesity in mouse models. Published in Cell Reports, the discovery offers a metabolic‑focused alternative to appetite‑suppressing drugs and could reshape biohacking approaches to...
Genome Sequencing Drops From Billions to Kitchen‑table Affordability
Human genome sequencing: 2003: $3,000,000,000 global effort years of research 2026: your kitchen table a few hundred $ Hard not to be excited for the future. https://t.co/0U5bXsHwt6 https://t.co/0U5bXsHwt6
Unexpected Insight Among 11 Lessons From AACR26
11 things I learned at #AACR26 Industry Partnering event – number 7 may well surprise you: https://t.co/T0ePbaIU1K https://t.co/CMh15HfnnG
The Longevity Effects of Reduced IGF-1 Signaling Depend on the Stability of the Mitochondrial Genome (Paper April 2026)
The study shows that reducing IGF‑1 signaling via Pappa loss does not extend lifespan in Polg D257A mutator mice, which harbor unstable mitochondrial DNA. While Pappa deletion improves several health metrics—splenomegaly, anemia, inflammation, muscle and cardiac function—the longevity benefit seen in...
KRAS Targeting Fuels $30B Valuation for RVMD
The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades Or, how $RVMD is now worth $30B https://t.co/iFilUpezjn via @angRchen #AACR26
Order Set to Speed Psychedelic Drug Research Access
the order will dramatically accelerate access to new medical research and treatments based on psychedelic drugs
HHS Partners to Boost Psychedelic Trial Data, Prioritize Breakthroughs
HHS will work with the Department of Veterans Affairs, as well as the private sector, to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, and shall prioritize drugs that have received Breakthrough Therapy status